Timely Disclosure Information(past list)

2025

January 15, 2025	StemRIM Announces the Extension of the Term for the Tripartite Joint Research Agreement Aimed at Elucidating Skin Anti-Aging Mechanisms

2024

December 23, 2024	StemRIM Announces the First Administration of Phase 2 Clinical Trial for Redasemtide Targeting Ischemic Cardiomyopathy
December 12, 2024	[Delayed]StemRIM Announces Selection for the AMED Project “FY2024 Project for Fundamental Technology Development toward Industrialization of Regenerative Medicine and Gene Therapy”
December 11, 2024	StemRIM Announces Completion of Payment for Issuance of New Shares as Restricted Stock Compensation
December 09, 2024	StemRIM Announces Patent Registration (Europe) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy and Chronic Heart Failure Caused Thereby
December 05, 2024	StemRIM Announces Patent Registration in Australia for Peptides Related to the HMGB1 Fragment Peptide, Redasemtide
November 13, 2024	StemRIM Announces Issuance of New Shares as Remuneration for Restricted Stock
November 05, 2024	StemRIM Announces Patent Registration in Japan for the HMGB1 Peptide, Redasemtide
October 31, 2024	Presentation Material for Business Plan and Growth Potential
September 25, 2024	Notice Regarding Appointment of Director Candidates
September 25, 2024	StemRIM Announces Proposal for Approval of Issuance of Stock Options to our Company’s Executive Officers, Employees, and External Collaborators
September 11, 2024	Notice Regarding Differences between Non-consolidated Result s for Fiscal Year Ended July 31, 2024 and those for Previous Fiscal Year
August 09, 2024	StemRIM Announces Fixed Details of the Issuance of Stock Options to Temporary Employees and External Collaborator
August 08, 2024	StemRIM Announces Patent Registration in China for Peripheral Peptides of the HMGB1 Fragment Peptide, Redasemtide
July 26, 2024	StemRIM Announces Fixed Details of the Issuance of Stock Options to Employees
July 26, 2024	StemRIM Announces Fixed Details of the Issuance of Stock Options to Directors
July 25, 2024	StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Directors
July 25, 2024	StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Employees
July 25, 2024	StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Temporary Employees and External Collaborator
July 08, 2024	StemRIM Announces Patent Registration in Japan for Stem Cell Gene Therapy for Dystrophic Epidermolysis Bullosa
June 17, 2024	StemRIM Announces Patent Registration (Australia) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy and Old Myocardial Infarction
May 08, 2024	StemRIM Announces Setting the Record Date for Extraordinary General Meeting of Shareholders Convening and Holding of Extraordinary General Meeting of Shareholders, and Reduction of Capital Stock (Capital Decrease)
March 13, 2024	StemRIM Announces Initiation of Phase 2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy
February 29, 2024	StemRIM Announces Fixed Details of the Issuance of Stock Options to External Collaborators
February 15, 2024	StemRIM Announces Patent Registration (Japan) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication of Traumatic Cartilage Deficiency Syndrome, Osteoarthritis, and Disseverance Osteochondritis
February 14, 2024	StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to External Collaborators
January 31, 2024	StemRIM Announces Patent Registration (Russia) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders (Traumatic Cartilage Deficiency Syndrome, Osteoarthritis, Disseverance Osteochondritis, etc.)

2023

December 28, 2023	StemRIM Announces Fixed Details of the Issuance of Stock Options to External Collaborator
December 13, 2023	StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to External Collaborator
December 06, 2023	StemRIM Announces Completion of Payment for Issuance of New Shares as Restricted Stock Compensation
December 04, 2023	StemRIM Announces Conclusion of Agreement for the Initiation of a Phase2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy
November 16, 2023	[Delayed]StemRIM Announces Extension of the Tripartite Collaborative Research Agreement Updated on January 24, 2023
November 16, 2023	[Delayed]StemRIM Announces Issuance of New Shares as Remuneration for Restricted Stock
October 27, 2023	[Delayed]StemRIM Announces Change of Representative Directors
September 28, 2023	StemRIM Announces Fixed Details of the Issuance of Stock Options to Temporary Employee and External collaborator
September 28, 2023	[Delayed]StemRIM Announces Proposal for Approval of Issuance of Stock Options to our Company’s Executive Officers, Employees, and External Collaborators
September 20, 2023	[Delayed]StemRIM Announces Fixed Details of the Issuance of Stock Options to Employee
September 20, 2023	[Delayed]StemRIM Announces Fixed Details of the Issuance of Stock Options to Director
September 19, 2023	[Derayed]Presentation Material, Financial Results for the Fiscal Year Ended July 31, 2023
September 19, 2023	[Delayed]StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Temporary Employee and External collaborator
September 19, 2023	[Delayed]StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Employee
September 19, 2023	[Delayed]StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Director
September 06, 2023	StemRIM Announces Patent Registration (US) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy (Dilated Cardiomyopathy, Ischemic Cardiomyopathy, and Hypertensive Cardiomyopathy)
September 04, 2023	StemRIM Announces Patent Registration (China) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy and Old Myocardial Infarction
July 31, 2023	StemRIM Announces the First Administration of Global Late Phase 2 Clinical Trials for Redasemtide (HMGB1 Peptide) Targeting Acute Ischemic Stroke (Japan)
July 25, 2023	StemRIM Announces the Initiation of Global Late Phase 2 Clinical Trials for Redasemtide (HMGB1 Peptide) Targeting Acute Ischemic Stroke (Europe, China)
July 18, 2023	StemRIM Announces Patent Registration (Korea) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy and Old Myocardial Infarction
May 24, 2023	StemRIM Announces Orphan Drug Designation of Regeneration-Inducing Medicine Redasemtide (HMGB1 peptide)
May 22, 2023	StemRIM Announces Results from Phase 2 Clinical Trial of Redasemtide in Patients with Chronic Liver Disease (Additional Report)
May 19, 2023	[Delayed]StemRIM Announces Patent Registration (Taiwan) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Therapeutic Indication for Cardiomyopathy and Old Myocardial Infarction
April 28, 2023	StemRIM Announces Milestone Achievement in Development of Therapeutic Drug (Redasemtide) Targeting Acute Ischemic Stroke
April 11, 2023	[Delayed] StemRIM Announces Preliminary Results from Phase 2 Clinical Trial of Redasemtide in Patients with Chronic Liver Disease
April 11, 2023	[Delayed] Notice of Earnings Forecasts for the Fiscal Year Ending July 31, 2023
April 11, 2023	[Delayed] StemRIM Announces Milestone Achievement in Development of Therapeutic Drug (Redasemtide) Targeting Acute Ischemic Stroke